Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that in mouse models, the novel NF-κB inhibitor DHMEQ improved symptoms of atopic dermatitis as effectively as tacrolimus or betamethasone.

The document concludes that various topical medications are effective for skin conditions but often cause skin irritation as a side effect.

This study suggests that PF-0998425 is an effective androgen receptor antagonist for sebum control and androgenetic alopecia with rapid metabolism reducing the risk of systemic side effects.

This review discusses the use of topical immunotherapy for severe alopecia areata and resistant viral warts, highlighting diphencyprone's advantages and the need for careful handling to avoid staff sensitisation; it reports no new clinical results.

This report discusses the FDA's rejection of Aveed, a long-acting testosterone injection, due to safety concerns despite divided advisory committee opinions, without presenting new clinical data.

This study concluded that 0.05% betamethasone dipropionate cream is more effective than other topical treatments for improving alopecia areata over 12 weeks.

This study found that a single topical application of calcipotriol ointment did not affect systemic calcium levels in patients with chronic plaque psoriasis.

This study found that adherence to topical hydrocortisone in adults with atopic dermatitis was inconsistent and not significantly different across different medication vehicles, though disease severity improved markedly within 2 weeks.

This study found no significant difference in effectiveness between 0.05% desonide cream and 1.0% hydrocortisone cream for treating seborrheic dermatitis over 8 weeks, with neither causing skin atrophy.

This study found that topical diphenylcyclopropenone was effective in treating severe alopecia areata but had a high relapse rate and was often accompanied by side effects like eczema and lymphadenopathy.

The combination of tretinoin, minoxidil, and betamethasone valerate may cause severe scalp inflammation.

This study demonstrated that a new topical treatment using ketotifen-loaded microneedles, designed for prolonged release, significantly reduced inflammatory markers in an animal model of allergic conjunctivitis, suggesting enhanced therapeutic delivery and sustained ocular benefits.

This review summarizes the pharmacology, mechanisms, and clinical efficacy of topical immunotherapy for alopecia areata but reports no new clinical results.

This review discusses the safety of dermatological medications used during pregnancy, highlighting that retinoids have strong teratogenic risks and should be used with caution; it reports no new clinical results.

This study found that among patients with twenty-nail dystrophy, those treated with oral cyclosporine in combination with a dietary supplement showed significantly better improvement in nail condition and quality of life than those treated with the supplement alone.

This study reports that diphenylcyclopropenone topical immunotherapy resulted in any hair regrowth for 69% of patients with alopecia areata, but with common side effects including mild to severe contact dermatitis.

Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.

This study developed a niosomal delivery system loaded with tretinoin and bicalutamide, optimized for follicular targeting in acne management, showing promising accumulation in hair follicles in animal models.

This chapter reviews various dermatological drugs and treatments, highlighting adverse effects, with no new clinical findings reported.

This report describes a case in which the use of the beta-blocker nadolol was associated with infiltrative dermatitis and significant alopecia, which resolved and resulted in total hair regrowth after discontinuation of the drug.

This report discusses the FDA's third denial of approval for Aveed, a long-acting testosterone injection by Endo Pharmaceuticals, citing continued safety concerns including severe side effects.

In this study, the combination of topical minoxidil 5% and betamethasone valerate 0.1% achieved slightly higher depigmentation in vitiligo of hair-bearing areas but did not show significant improvement over betamethasone valerate alone.

This case report documents a patient experiencing paradoxical depigmentation of the periocular skin after one year of using latanoprost, a finding not previously associated with this medication.

In this study, oral dienogest combined with ethinylestradiol provided effective contraception with a Pearl Index of approximately 0.2 and improved androgenic symptoms without significant metabolic effects.

This article reviews the usage, efficacy, side effects, and alternatives of topical bimatoprost 0.03% for dermatological applications but does not present new clinical findings.

This study reviewed evidence suggesting that systemic corticosteroids, particularly in pulse regimens like dexamethasone and betamethasone oral mini-pulse, effectively slow vitiligo progression and support repigmentation, while offering a favorable safety profile compared to continuous therapy.

This study found that topical corticosteroid foams are effective and generally preferred by patients for a variety of corticosteroid-responsive skin conditions, demonstrating significant clinical benefits such as improved psoriasis symptoms and hair regrowth in alopecia areata compared to traditional forms.

In this study, no significant difference was found between the efficacy of betamethasone dipropionate cream and placebo in treating alopecia areata in children, regardless of atopic status.